Published in Cancer Res on November 01, 1998
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A (2007) 2.10
VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol (2006) 2.03
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol (2007) 1.62
Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol (2010) 1.55
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol (2004) 1.45
VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol (2001) 1.31
Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci U S A (2005) 1.17
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem (2006) 1.13
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One (2010) 1.12
Identification of Jade1, a gene encoding a PHD zinc finger protein, in a gene trap mutagenesis screen for genes involved in anteroposterior axis development. Mol Cell Biol (2003) 0.98
Growth factors in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 0.88
Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer (2013) 0.87
Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer (2009) 0.87
HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. Cancer Cell Int (2007) 0.87
Expression of VHL Causes Three-Dimensional Morphological Changes in Renal Cells Indicative of Proximal Tubule Differentiation. Cell Dev Biol (2013) 0.80
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid. Endocr Pathol (2000) 0.79
Sodium butyrate enhances the growth inhibitory effect of sunitinib in human renal cell carcinoma cells. Oncol Lett (2017) 0.75
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med (1995) 3.86
Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell (1989) 3.81
Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res (1993) 3.59
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell (1998) 3.22
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells. Eur J Immunol (1972) 2.34
Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst (1994) 2.25
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev (2001) 2.16
The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell (1974) 2.12
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93
Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1990) 1.93
Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84
Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med (1997) 1.82
Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. J Immunol (1971) 1.80
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol (1992) 1.66
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66
A cancer therapy resistant to resistance. Nature (1997) 1.65
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer (1997) 1.48
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45
Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res (2000) 1.42
Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39
Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int (2000) 1.38
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res (1988) 1.36
Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum. Cell Immunol (1974) 1.35
Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol (1983) 1.32
Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31
New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis (2008) 1.31
Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol (1998) 1.30
Establishing a link between oncogenes and tumor angiogenesis. Mol Med (1998) 1.29
Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol (1997) 1.27
Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27
Aggressive angiomyxoma of pelvic soft parts: a clinicopathologic study of nine cases. Hum Pathol (1985) 1.24
Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer (1978) 1.24
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res (2000) 1.24
Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J (2001) 1.23
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene (2006) 1.21
Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Curr Biol (1998) 1.20
Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol (1995) 1.20
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20
Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (1996) 1.20
Cell adhesion and drug resistance in cancer. Curr Opin Oncol (1997) 1.18
Origin of chemiluminescence accompanying the reaction of the 9-cyano-10-methylacridinium cation with hydrogen peroxide. J Org Chem (2004) 1.18
'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer (2000) 1.18
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17
Measurement of direct photon production in p+p collisions at sqrt[s] = 200 GeV. Phys Rev Lett (2007) 1.16
Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer (1975) 1.14
Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene (2000) 1.12
Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol (1993) 1.12
CD44 and the adhesion of neoplastic cells. Mol Pathol (1997) 1.12
Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett (2010) 1.12
Particle-yield modification in jetlike azimuthal dihadron correlations in Pb-Pb collisions at √s(NN)=2.76 TeV. Phys Rev Lett (2012) 1.11
An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst (1976) 1.11
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer (1999) 1.10
Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. Cancer Res (1988) 1.10
Magnetic resonance thermometry for predicting thermal damage: an application of interstitial laser coagulation in an in vivo canine prostate model. Magn Reson Med (2000) 1.10
Adhesion-dependent multicellular drug resistance. Anticancer Drug Des (1999) 1.09
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol (1997) 1.09
Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A (1990) 1.09
TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene (1996) 1.09
High-frequency color flow imaging of the microcirculation. Ultrasound Med Biol (2000) 1.09
The role of membrane proteins and phospholipids in the interaction of ribosomes with endoplasmic reticulum membranes. Can J Biochem (1975) 1.08
Further studies of antigenic competition. 3. A model to account for the phenomenon based on a deficiency of cell-to-cell interaction in immune lymphoid cell populations. J Exp Med (1971) 1.08
Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer (1991) 1.08
Transverse momentum distribution and nuclear modification factor of charged particles in p+Pb collisions at sqrt[s(NN)] = 5.02 TeV. Phys Rev Lett (2013) 1.08
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ (2011) 1.07
Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res (1998) 1.06
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res (1995) 1.06
Cell-surface levels of human carcinoembryonic antigen are inversely correlated with colonocyte differentiation in colon carcinogenesis. Lab Invest (1997) 1.06
Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc (2000) 1.06
Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. J Natl Cancer Inst (1989) 1.06